Dynamic bidirectional regulation of NLRC3 and gammaherpesviruses during viral latency in B lymphocytes

© 2024 Wiley Periodicals LLC..

While most NOD-like receptors (NLRs) are predominately expressed by innate immune cells, NLRC3, an inhibitory NLR of immune signaling, exhibits the highest expression in lymphocytes. The role of NLRC3 or any NLRs in B lymphocytes is completely unknown. Gammaherpesviruses, including human Epstein-Barr virus (EBV) and murine gammaherpesvirus 68 (MHV-68), establish latent infection in B lymphocytes, which requires elevated NF-κB. This study shows that during latent EBV infection of human B cells, viral-encoded latent membrane protein 1 (LMP1) decreases NLRC3 transcript. LMP1-induced-NF-κB activation suppresses the promoter activity of NLRC3 via p65 binding to the promoter. Conversely, NLRC3 inhibits NF-κB activation by promoting the degradation of LMP1 in a proteasome-dependent manner. In vivo, MHV-68 infection reduces Nlrc3 transcripts in splenocytes, and Nlrc3-deficient mice show greater viral latency than controls. These results reveal a bidirectional regulatory circuit in B lymphocytes, where viral latent protein LMP1 reduces NLRC3 expression, while NLRC3 disrupts gammaherpesvirus latency, which is an important step for tumorigenesis.

Medienart:

E-Artikel

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Zur Gesamtaufnahme - volume:96

Enthalten in:

Journal of medical virology - 96(2024), 3 vom: 01. März, Seite e29504

Sprache:

Englisch

Beteiligte Personen:

Kang, Hye-Ri [VerfasserIn]
Han, Ji Ho [VerfasserIn]
Ng, Yee Ching [VerfasserIn]
Ryu, Seungbo [VerfasserIn]
Park, Ji-Yeon [VerfasserIn]
Chung, Woo-Chang [VerfasserIn]
Song, Yoon-Jae [VerfasserIn]
Chen, Szu-Ting [VerfasserIn]
Brickey, W June [VerfasserIn]
Ting, Jenny P-Y [VerfasserIn]
Song, Moon Jung [VerfasserIn]

Links:

Volltext

Themen:

B lymphocytes
EBV
Gammaherpesvirurses
Intercellular Signaling Peptides and Proteins
Journal Article
LMP1
MHV-68
NF-κB
NF-kappa B
NLRC3
NLRC3 protein, human
NLRC3 protein, mouse
Tumorigenesis
Viral latency

Anmerkungen:

Date Completed 07.03.2024

Date Revised 07.03.2024

published: Print

Citation Status MEDLINE

doi:

10.1002/jmv.29504

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM369356306